Breaking News Headlines Today | Ground News

See every side of every news story

Pharmaceutical-technology.com image

News from pharmaceutical-technology.com

See all of Pharmaceutical-technology.com’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources.

In total, 340 have been published by Pharmaceutical-technology.com which Ground News has aggregated in the past 3 months.

Ground News rates Pharmaceutical-technology.com’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Pharmaceutical-technology.com’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Pharmaceutical-technology.com

Where is Pharmaceutical-technology.com located?Pharmaceutical-technology.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Pharmaceutical-technology.com News

Trump threatens to impose up to 200% tariff on pharmaceuticals ‘very soon’

Trade War · United States

Trump threatens to impose up to 200% tariff on pharmaceuticals ‘very soon’

40% Left coverage: 73 sources

WHO Endorses Twice-Yearly Lenacapavir Injections for HIV Prevention

World Health Organization

WHO Endorses Twice-Yearly Lenacapavir Injections for HIV Prevention

79% Center coverage: 43 sources

Health Canada Extends Evkeeza Approval to Treat HoFH in Infants

Health Canada · Canada

Health Canada Extends Evkeeza Approval to Treat HoFH in Infants

57% Left coverage: 7 sources

Health Canada has announced an important update in the treatment of homozygous familial hypercholesterolemia (HoFH), extending the approval of Evkeeza® (evinacumab) to include children as young as six months old. This development marks a significant advancement in managing the rare genetic disorder characterized by dangerously high cholesterol levels from an early age. The expanded authorization aims to provide younger patients with improved acc…See the Story

LEO Bulks up with Deal for Boehringer Skin Drug

100% Center coverage: 1 sources

LEO Pharma has licensed a medicine for a rare form of psoriasis from Boehringer Ingelheim, plugging a gap in its near-term product portfolio.Pharma See the Story

New Cystic Fibrosis Triple From Vertex Backed for NHS Use

100% Center coverage: 1 sources

Vertex has won NICE's backing for a new cystic fibrosis therapy, Alyftrek, that could be an option for 89% of NHS patients with the genetic disorder.NHS · England See the Story

Sino Biopharma spends $951m to acquire China-based LaNova Medicines – EMEA Tribune – Latest News – Breaking News – World News

Hong Kong-listed Sino Biopharmaceutical will acquire China-based oncology specialist LaNova Medicines in a deal that will not exceed $951m, representing one of the largest transactions […] SourceChina · China See the Story

Otsuka to acquire Cantargia’s CAN10 for autoimmune diseases

Otsuka Pharmaceutical has signed an agreement to acquire all assets related to Cantargia's early-clinical stage CAN10 programme.Japan · Japan Read Article

South Africa: Government Is Considering Providing a Vaccine to Protect Babies From RSV

100% Center coverage: 1 sources

Blog - A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa's private sector but not yet in public clinics. The country's advisory group on immunisations has recommended making it available to all pregnant women. This proposal is now under review by the National Department of Health.Vaccines · United States See the Story

Vertex Secures Alyftrek Coverage in England; Merck Starts Phase 3 Trials of HIV Drug

100% Center coverage: 1 sources

NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill into late-stage trials.NHS See the Story

Illimis Secures Funding for GAIA-Based Alzheimer's Therapeutics

Illimis has completed a Series B funding round, securing $42m for the development of its GAIA-based Alzheimer's disease therapeutics.Alzheimer's Disease · Seoul See the Story

Pledging ‘Radical Transparency,’ FDA Reveals Drug Rejection Letters — With Limits

100% Center coverage: 1 sources

The FDA published more than 200 complete response letters, the first step in what it describes as part of its effort to modernize the agency and improve transparency. But there are some caveats to the release of the FDA correspondence. The post Pledging ‘Radical Transparency,’ FDA Reveals Drug Rejection Letters — With Limits appeared first on MedCity News.Silver Spring · Silver Spring See the Story

Breaking News Topics Related to Pharmaceutical-technology.com